RxDoctor Payments Data

Dennis Marcelo, MD

Pain Medicine · Hattiesburg, MSNPI 1417343559

Payments from drug & device makers

What this record shows

22 manufacturers reported payments, led by Abbott at 49.9% of the total. Reporting peaked in 2019 at $3,349 and has fallen 90.7% since, to $310 in 2025.

$9,988in general payments, 2019–2025

Across 187 payments — averaging $53.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Boston Scientific$2K
  • Spinal Simplicity, LLC$1K
  • Medtronic$613
  • Si-bone, Inc.$204
  • Tersera Therapeutics LLC$166
  • plus $635 from 16 others

What the payments were for

  • Travel & lodging$4,07641%
  • Food & beverage$5,91259%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,988 in reported general payments places this provider in the 75th percentile of 48 pain medicine providers in Mississippi.

See all pain medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$216,830
Medicare patients
327
Services billed
4,977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate40$21,176
OxycontinOxycodone Hcl12$6,607
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen142$2,700
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen98$2,487
Oxycodone Hcl96$1,427
Morphine Sulfate ErMorphine Sulfate37$980
Pregabalin49$886
Gabapentin43$711
Morphine Sulfate17$567
Methadone Hcl17$433
Tramadol Hcl52$362
Hydromorphone Hcl21$359
Baclofen15$239
Amitriptyline Hcl15$197
Cyclobenzaprine Hcl16$176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$31$21,17640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 48 pain medicine providers in Mississippi.

Other pain medicine in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →